Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Recruiting now · Early Phase 1

Conditions studied: Allogeneic Hematopoietic Cell Transplantation

In brief

The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.

Key facts

Study ID

NCT04332341

Run by

Case Comprehensive Cancer Center

People needed

20

Starts

2020-05-19

Expected to finish

2026-09-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
• Subject must meet program eligibility criteria* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
• HLA-identical related donor or unrelated human donor source with bone marrow graft.
• Subjects must provide a written informed consent.

You may not qualify if…

• History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
• Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
• Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

Where it is running

• Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.